Journal: Expert opinion on therapeutic patents

Article Title: Deuterated drugs; where are we now?

doi: 10.1517/13543776.2014.943184

Figure Lengend Snippet: Major Pharma Companies Recent First Disclosure Drug Deuterium Pharmacokinetic Improvements in US Patent Applications

Article Snippet: Therefore, it would appear that such an analysis could support priority dates up to about 2009 to 2010 based upon a majority of major pharmaceutical companies (containing many such scientists skilled in the art) making their first specific drug deuteration claims, or as late as 2013 based upon the last major company to do so. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Figure 2 caption a7 Time course of major pharma companies first disclosing drug deuterium pharmacokinetic improvements in US Patent applications. table ft1 table-wrap mode="anchored" t5 caption a7 Company Year Title Pfizer 2002 Benzophenones and sulfones [ 85 ] Merck 2005 Pyridazine Derivatives [ 86 ] (excludes Reinhold [ 1 ]) Glaxo SmithKline 2006 Pyrimidine derivatives and [ 87 ] Wyeth 2007 41-Methoxy isotope labeled [ 88 ] Novartis 2009 Organic Compounds [ 89 ] Astra Zeneca 2009 Allosteric modulators of [ 90 ] Roche 2009 Thiazolopyrimidine p13k inhibitor [ 91 ] Abbott 2010 Compounds useful as [ 92 ] Bristol-Myers Squib 2010 Compounds for the [ 93 ] Eli Lilly 2010 Modified bovine g-CSF [ 94 ] Bayer 2012 Substituted 5-fluoro-1H-pyrazolopyridines [ 95 ] Sanofi-Aventis 2012 9h-pyrrolo[2,3-b: 5,4-c'] dipyridine azacarboline [ 96 ] Johnson and Johnson 2013 Process for the [ 97 ] Open in a separate window Major Pharma Companies Recent First Disclosure Drug Deuterium Pharmacokinetic Improvements in US Patent Applications

Techniques: Labeling, Modification